ArticleEpidemiology and infection2019
Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters.
Article in Epidemiology and infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens (Basel, Switzerland) · 2024Pooled it
- VP1 molecular evolution of type 2 immunodeficiency-related vaccine-derived polioviruses (iVDPV2) in a patient with primary immunodeficiency disease (PID).Virus genes · 2026Article
- Characterization of environmental and clinical surveillance inputs to support prospective integrated modeling of the polio endgame.PLOS global public health · 2025Review
- Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management.Pathogens (Basel, Switzerland) · 2024Review
- Modeling Poliovirus Transmission and Responses in New York State.The Journal of infectious diseases · 2024Article
- Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- Article
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.Expert review of vaccines · 2022Article
- Stool Serology: Development of a Non-Invasive Immunological Method for the Detection of Enterovirus-Specific Antibodies in Congo Gorilla Faeces.Microorganisms · 2021Article
- Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Potential Future Use, Costs, and Value of Poliovirus Vaccines.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.Medical decision making : an international journal of the Society for Medical Decision MakingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conditions and evidence continue to evolve related to the prediction of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters, which affect assumptions related to forecasting risks and evaluating potential risk management options. Multiple recent reviews provided information about individual iVDPV excreters, but inconsistencies among the reviews raise some challenges. This analysis revisits the available evidence related to iVDPV excreters and provides updated model estimates that can support future risk management decisions. The results suggest that the prevalence of iVDPV excreters remains highly uncertain and variable, but generally confirms the importance of managing the risks associated with iVDPV excreters throughout the polio endgame in the context of successful cessation of all oral poliovirus vaccine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.